Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave CEO Bought 5,000 Shares After Stock Fell

NEW YORK, March 17 (GenomeWeb News) - John Puisis, CEO of Third Wave Technologies, purchased 5,000 of his company's shares on March 15 at the low point of a stock-price slide precipitated by disappointing fourth quarter earnings, GenomeWeb News has learned.


Third Wave's share price reached $4.53 when Puisis made the recent purchase. John Nies, a Third Wave director, purchased 5,000 shares on March 11 at $4.77. The shares, which have more than regained the ground they lost since the decline, were up 5.34 percent, or $.26, at $5.11 in late-afternoon trading today. However, they are still short of the stock's 52-week high of $9.08.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.